Contemporary views of tumorigenesis regard its inception as a convergence of genetic mutation and developmental context. Glioma is the most common and deadly malignancy in the CNS; therefore, understanding how regulators of glial development contribute to its formation remains a key question. Previously we identified nuclear factor I-A (NFIA) as a key regulator of developmental gliogenesis, while miR-223 has been shown to repress NFIA expression in other systems. Using this relationship as a starting point, we found that miR-223 can suppress glial precursor proliferation via repression of NFIA during chick spinal cord development. This relationship is conserved in glioma, as miR-223 and NFIA expression is negatively correlated in human glioma tumors, and the miR-223/NFIA axis suppresses tumorigenesis in a human glioma cell line. Subsequent analysis of NFIA function revealed that it directly represses p21 and is required for tumorigenesis in a mouse neural stem cell model of glioma. These studies represent the first characterization of miR-223/ NFIA axis function in glioma and demonstrate that it is a conserved proliferative mechanism across CNS development and tumorigenesis.
Introduction
The majority of CNS malignancies are glial in composition and origin, with glioma representing the most prevalent and deadly CNS tumor . A cardinal feature of glioma is a heterogeneous tumor mass that is largely comprised of pathological glial cells and their precursors, making the molecular and cellular processes that regulate gliogenesis potential therapeutic targets Stiles and Rowitch, 2008) . Indeed, the neural stem cell (NSC)/glial differentiative axis has previously been linked to glioma formation, with key transcriptional regulators of developmental gliogenesis having been implicated in tumorigenesis, including Olig2 and STAT3 (Ligon et al., 2007; de la Iglesia et al., 2008) . While these studies indicate common transcriptional requirements for glial development and glioma tumorigenesis, how developmental gliogenesis contributes to tumorigenesis remains a poorly understood process that has important implications for the treatment of this largely fatal disease.
Previous studies identified nuclear factor I-A (NFIA) as a key transcription factor in the specification of glial identity and differentiation of astrocytes during spinal cord development (das Neves et al., 1999; Shu et al., 2003; Namihira et al., 2009) . Mechanistic studies into NFIA function during development indicate that it collaborates with Sox9 to regulate genetic programs associated with glial precursor metabolism and migration, two key developmental processes implicated in tumorigenesis (Kang et al., 2012) . Previously, we also found that NFIA is overexpressed in human astrocytomas and glioblastoma multiforme (GBM; Song et al., 2010) . Despite this knowledge and the extensive characterization of its function during glial development, its role in glioma tumorigenesis remains uncharacterized.
MicroRNAs (miRNAs) have emerged as critical regulatory elements that control gene expression in development and tumorigenesis (Dalmay and Edwards, 2006) . In the hematopoietic system, miR-223 plays a key role in both development and tumorigenesis. In myeloid progenitors and myeloid leukemia, miR-223 suppresses cell proliferation; however, reduced expression is associated with enhanced survival, implying a more nuanced role for miR-223 in the myeloid lineage (Fazi et al., 2007; Stamatopoulos et al., 2009; Sun et al., 2010) . In GBM, in silico analysis and bioinformatics has linked miR-223 expression to the proneural subtype, though its expression or function in glioma has not been validated in human tumors or models (Genovese et al., 2012) .
Studies in the hematopoietic system indicate that miR-223 regulates expression of NFIA, though this relationship has not been characterized in the developing CNS and glioma tumorigenesis (Fazi et al., 2005) . Given that both NFIA and miR-223 appear to be expressed in GBM, we reasoned an analogous regulatory relationship that exists during hematopoiesis also exists in the developing CNS and glioma tumorigenesis. Here we found that miR-223 suppresses glial precursor proliferation via repression of NFIA in the developing CNS. This relationship is conserved in human glioma, as miR-223 and NFIA expression is negatively correlated in human GBM, and the miR-223/NFIA axis suppresses glioma tumorigenesis. These studies represent the first characterization of miR-223/NFIA axis function in the CNS and reveal that it is a conserved proliferative mechanism across CNS development and tumorigenesis.
Materials and Methods
Chick experiments. Expression constructs were cloned into the RCAS(B) (Morgan and Fekete, 1996) , pCIG, or pEZX vectors and injected into the chick spinal cord at stage HH13-15 [approximately embryonic day 2 (E2)]. Harvested embryos were fixed in 4% PFA for 2-4 h, depending on stage. Electroporation was performed with a BTX Electro Square Porator (Momose et al., 1999) . In situ hybridization (ISH) and immunocytochemistry (ICC) analysis was performed as described previously (Kang et al., 2012) .
Antibodies. Antibodies used for immunohistochemistry (IHC), chromatin immunoprecipitation (ChIP), and Western blotting in these studies were ␣-␤-tubulin (Covance), ␣-BrdU (Abcam), ␣-caspase (R & D Systems), ␣-epidermal growth factor receptor (␣-EGFR; DAKO), ␣-Gapdh (Millipore Bioscience Research Reagents), ␣-Ki67 (DAKO; Novocastra), ␣-Nestin (BD Biosciences), ␣-NeuN (Millipore), ␣-NFIA (Abcam), and ␣-SV40 (Santa Cruz Biotechnology).
Rat cortical culture. Rat embryonic E14.5 cortices were dissected, dissociated, then plated at a density of 2 ϫ 10 4 cells/cm 2 on plates coated with 15 g/ml polyornithine (Sigma) and 1 g/ml human fibronectin (Biochemical Technologies). Cells were grown in DMEM/F-12 supplemented with N2 and B27 (Invitrogen) and 20 ng/ml bFGF (R & D Systems), as described by Gabay et al. (2003) . Cells were expanded for 4 d followed by transfection with Lipofectamine 2000. BrdU (10 M) was added to media and incubated for 4 -6 h, followed by immunofluorescent BrdU detection.
Analysis of NFIA and miR-223 in human GBM. Glioblastoma (GBM) and normal tissue array (US Biomax GL806a) was subjected to in situ hybridization and immunohistochemistry. GBM samples from these tissue arrays were not classified into subtypes. Exiqon miRCURY LNAmiR-223 or control probe was used according to manufacturer's directions. Immunohistochemistry for NFIA and Ki-67 was performed using DAB and ABC reagent kits (Vector Laboratories). For statistical analyses, using the NFIA and miR-223 correlation as a specific example, Log2 transformation was applied to expression data across 24 tumor samples, and the profiles for miR-223 and NFIA had Pearson correlation coefficients (PCCs) of Ϫ0.39, and Spearman's rank correlations (rho) of Ϫ0.41, both indicating significant negative correlations ( p ϭ 0.03 for PCC and p ϭ 0.02 for Spearman's rho). With NFIA serving as observation, least squares regression gave a linear model with slope Ϫ0.905 and an R 2 value of 0.155. The quadratic function fitted by least squares regression showed an improved R 2 value (0.188) and clear trends of negative correlation between log2 scale profiles of miR-223 and NFIA. This same analysis was performed in the correlation of miR-223/Ki-67 and NFIA/Ki67. All above analysis were done using the statistics toolbox of Matlab 7.1 (R14).
Generation of cell lines and in vitro proliferation assays. Lentiviruses containing miR-223 or scrambled control were generated, and the human U87 glioma cell line was infected. Shortly after infection, cell lines were subjected to puromycin selection to generate stably expressing populations. For NFIA rescue experiments, the U87-miR-223 cell line was infected with a lentivirus containing NFIA and dsRed, and was enriched using FACS analysis. Once generated, cell lines were stored or used for up to six passages. Thereafter, new cells were thawed and resubjected to puromycin selection for subsequent experiments. For proliferation assays, cells were plated and counted every day over the course of 6 d. For the cell cycle analysis, U87 cell lines were harvested and fixed with 70% ethanol for 2 h. After several 1ϫ PBS washes, cells were resuspended in a propidium iodide/Triton X-100 staining solution with RNaseA for 30 min at 37°C. Cells were collected and resuspended in FACS buffer for analyses on FACS Aria. Cell cycle distributions were analyzed using FlowJO software. For soft agar assays, 5 ϫ 10 4 cells were plated in 10% FBS/Iscove's media mixed with 0.7% noble agar, and growth was monitored over the course of 2 weeks, as described by .
Tumor studies. Mouse injections were performed as described previously, using female severe combined immune deficiency (SCID) mice (Ahmed et al., 2010) . Mouse brains were injected with 2.5 ϫ 10 5 cells of the respective U87 cell lines that also coexpress luciferase. Tumor growth was monitored over 2 weeks by bioluminescent imaging of the luciferase. After 2 weeks mice were killed for analyses.
Mice were injected with BrdU (200 g/g body weight), and brains were harvested 16 h later. Brains were fixed overnight in 4% paraformaldehyde and sectioned for immunofluorescence or hemotoxylin and eosin staining.
For tumor-sphere experiments, neurospheres were infected with retroviruses containing SV40 LargeT and EGFR-vIII (Deneen and Denny, 2001; Bachoo et al., 2002) . Stable cell lines were generated via puromycin selection and expression confirmed via immunohistochemistry. Subsequently, 1 ϫ 10 6 cells of each cell line were injected subcutaneously into female SCID mice and visually monitored for tumor formation. Upon formation of a 1.5 cm tumor, the mice were killed and the tumor harvested. All animal studies were performed in accordance with institutional Institutional Animal Care and Use Committee policies and with prior approval.
Quantitative reverse transcriptase PCR and luciferase assays. Total RNA was isolated from cell lines using an RNeasy mini isolation kit (Qiagen). Superscript III (Invitrogen) was used for reverse transcription of 1 g of total RNA samples. Quantitative reverse transcriptase PCR (qRT-PCR) was performed using PerfeCta SYBR Green Fast Mix (Quanta Biosciences) and a LightCycler 480 (Roche). Primer sequences used are given in Table 1 .
For the luciferase assays, U87 and HEK293 cell lines cells were transfected with pGL3-reporter constructs and a pEZX or CMV-␤-galactosidase vector using Superfect transfection reagent (Qiagen). The p21-luciferase and NFIA 3ЈUTR-luciferase reporters were described previously (Fazi et al., 2005; Ligon et al., 2007) . Cells were harvested 48 h later and lysates analyzed for luciferase activity. ␤-galactosidase was used to normalize for transfection efficiency.
ChIP assays. U87 cell lines were harvested and processed for ChIP assay. Harvested cells were fixed with 1% formaldehyde for 10 min. Cross-linked chromatin was then sheared by sonication and cleared by centrifugation. The samples were precleared with protein G beads and immunoprecipitated using NFIA antibody or control IgG (Santa Cruz Biotechnology). Immunoprecipitated complexes were isolated, the cross-links reversed, and proteins digested with proteinase K. The DNA was purified, and PCR was performed using region-specific primers. Primer sequences used are given in Table 2 .
Neurosphere culture. Mouse E13.5 cortex was dissected, dissociated, and plated on ultra-low attachment plates in media containing DMEM/ F-12, B27 and N12 supplements (Invitrogen), 10 ng/ml EGF, and 10 ng/ml bFGF. Neurospheres formed in 4 -6 d. Neurospheres used in this study were passaged no more than three times. For BrdU incorporation assays, BrdU (10 M) was added to the media for 4 -6 h followed by immunofluorescent detection of BrdU. For differentiation experiments, neurospheres were plated on coverslips coated with 15 g/ml of polyor- 
1B-BЉ,E-EЉ).
The mutually exclusive expression dynamics in the developing CNS, coupled with our observation that the miR-223 target sequence is conserved across human, mouse, and chick ( Fig. 1G ), suggests that miR-223 suppresses NFIA expression. To test this possibility, we performed ectopic overexpression of miR-223 in the embryonic chick spinal cord and assessed its effect on NFIA expression. Our analysis revealed that overexpression of miR-223 resulted in decreased NFIA expression at E6 (Fig. 2B ), while the scrambled control had no effect (Fig. 2I ). Further analysis of the miR-223 overexpression phenotypes revealed decreased expression of the glial precursor marker GLAST without a concomitant increase in neurogenesis (Fig. 2C,D) . These observations suggest that miR-223 overexpression influences glial precursor proliferation. To assess cell proliferation, we analyzed proliferating cell nuclear antigen (PCNA) expression and found that it was decreased in the presence of miR-223 ( Fig. 2 E, V ). In addition, we performed BrdU labeling on chick embryos at E6 and found decreased incorporation in the presence of miR-223,without any effect on cell death or survival. (Fig. 2 F, W,X ). To confirm these observations in an in vitro setting, we performed analogous experiments in E14.5 rat cortical progenitor cultures and found a 50% decrease in BrdU incorporation in the presence of miR-223, compared to the scrambled control (Fig. 2G, N, Z) . Importantly, miR-223 overexpression did not alter the glial constituency of these cultures, further suggesting that it influences proliferation (Fig. 2Y ) . Together, our chick and glial culture studies indicate overexpression of miR-223 can suppress glial precursor proliferation during CNS development. Given the key role of NFIA in the specification of gliogenesis, we examined whether the decrease in glial precursor proliferation by miR-223 is caused by its suppression of NFIA. To this end, we coelectroporated miR-223 and an HA-tagged version of NFIA that does not contain the 3ЈUTR region targeted by miR-223 (Fig.  1G ). Analysis at E6 revealed that coexpression of NFIA with miR-223 rescued expression of PCNA and GLAST and restored BrdU incorporation levels to those comparable to the scrambled control, both in the chick and in vitro (Fig. 2O-Z) . Collectively, our data indicate that the suppression of glial precursor proliferation by miR-223 is mediated by its repression of NFIA expression.
miR-223/NFIA axis regulates glioma cell proliferation
Given that many developmental mechanisms are reused during tumorigenesis, it stands to reason that the processes regulating glial precursor proliferation during CNS development may also contribute to the generation of glial tumors. Therefore, we next examined whether the miR-223/NFIA regulatory axis contributes to the generation of glioma. As a first step in establishing this relationship, we examined the correlation of miR-223 and NFIA expression in human GBM tissue arrays using ISH and IHC, respectively (Fig. 3A-F ) . GBM is the most prevalent and deadly form of glioma, and is therefore a suitable model to examine this relationship. For each tumor, the number of miR-223-or NFIAexpressing cells found in adjacent patient tumor sections was quantified. These values were correlated across 24 patient samples and subjected to Spearman's rank correlation (rho), where we found that the expression of miR-223 and NFIA is negatively correlated across this set of GBMs (Fig. 3J ). Given our observation that the miR-223/NFIA axis regulates glial precursor proliferation during development, we next examined whether their expression in GBM is correlated with the proliferative marker Ki-67. Similar to the above studies, we used IHC to quantify the number of Ki-67-expressing cells in tumor array sections adjacent to those used in the above analysis. Our Spearman's rank correlation (rho) analysis found that Ki-67 is positively correlated with NFIA (Fig. 3K ) , while miR-223 is negatively correlated (Fig. 3L) . Together, these data suggest that the expression dynamics of the miR-223/NFIA axis is linked to proliferating populations within GBM.
That the expression of miR-223 and NFIA in GBM is congruent with their developmental patterns of expression suggests that their functional relationship may also be conserved. Therefore, we next investigated whether the miR-223/NFIA axis also regulates glioma proliferation by overexpressing miR-223 or scrambled control in the human U87 glioma cell line. Here we infected U87 cells with lentivirus containing miR-223 or scrambled control and generated stably expressing cell lines via drug selection. Upon the generation of a stable cell line, we confirmed expression of miR-223 via qRT-PCR and found that it both repressed activity of the NFIA 3ЈUTR reporter and suppressed NFIA protein expression, indicating that NFIA is a direct target of miR-223 in U87 glioma cells (Fig. 4 A, B) . Next we examined cell proliferation and found that the miR-223 overexpressing cell line grew significantly slower than the scrambled control and demonstrated an increase in the number of cells in G1 phase of the cell cycle (Fig.  4C,D) . To further assess the transforming properties of these tumor cell lines, we measured anchorage-independent growth by performing a soft agar assay. Consistent with our previous findings, the miR-223-expressing cell line demonstrated reduced growth in soft agar compared to the scrambled control (Fig. 4E-G) . Together, these data indicate that miR-223 suppresses the proliferation of a glioma cell line.
Next, we examined whether suppression of glioma cell proliferation by miR-223 is mediated by repression of NFIA expression. Here we generated lentivirus-containing NFIA and the dsRed reporter (or empty vector control), infected the existing the miR-223-expressing cell line with each virus, and generated stable cell lines via FACS isolation. Analysis of cell cycle and soft agar growth revealed that NFIA overexpression rescues the growth phenotypes manifest in the miR-223-expressing cell line ( Fig. 4D-G) . Collectively, our data indicate that, analogous to CNS development, suppression of glioma cell proliferation by miR-223 is mediated through its repression of NFIA.
miR-223/NFIA axis suppresses tumorigenesis and regulates p21 expression
The preceding data indicate that the miR-223/NFIA regulatory axis plays a crucial role in the proliferation of glial precursors during CNS development and in human glioma cell lines. Next we sought to determine whether miR-223 overexpression in glioma cell lines impacts tumorigenesis. To this end we injected U87 cells expressing miR-223, scrambled control, or miR-223ϩNFIA into the mouse brain and found that the cell lines overexpressing miR-223 demonstrated decreased tumor formation compared to the scrambled control (Fig. 5 A, B,J ). This reduction in tumor formation is correlated with decreased expression of Ki-67 (Fig.  5 D, E,K ) and BrdU incorporation (Fig. 5G, H, L) , linking the defects in cell proliferation to the impaired tumorigenesis. Furthermore, the effects of miR-223 on tumorigenesis and cell proliferation are rescued by overexpression of NFIA, indicating that repression of NFIA by miR-223 mediates these phenotypes (Fig. 5C, F 
, I-L).
We next sought to investigate the molecular mechanism by which the miR-223/NFIA axis regulates cell proliferation. NFI genes have been implicated in the regulation of p21, a key inhibitor of cell cycle and proliferation, whose dysregulation is associated with several malignancies, including glioma (Ouellet et al., 2006) . Given this potential link and our observation that miR-223 results in decreased NFIA expression and cell proliferation, we reasoned that the miR-223/NFIA axis regulates cell proliferation by modulating p21 expression. To test this hypothesis we performed qRT-PCR in U87 cells overexpressing miR-223 or the scrambled control and found that p21 expression is increased in the presence of miR-223 and correlated with reduced NFIA expression (Fig. 5M ) . Next we performed reporter assays with the p21 promoter and found that miR-223 results in increased p21 promoter activity compared to scrambled control, while NFIA blocks miR-223-induced activity and represses p21 activity on its own (Fig. 5N ) . These data suggest that increased p21 expression in the presence of miR-223 is the result of derepression due to reduced NFIA expression. That the p21 promoter contains several NFIA binding sites (Fig. 5O ) led us to hypothesize that it represses p21 expression by associating with the p21 promoter. To this end, we performed ChIP assays on U87 cells and found that NFIA associates with the p21 promoter, suggesting that it directly regulates p21 expression (Fig. 5P) . Together, these data indicate that the miR-223/NFIA axis plays a central role in glioma tumorigenesis by regulating key mechanisms that control cell cycle and proliferation.
NFIA regulates NSC proliferation and tumorigenesis
The foregoing epistasis and functional studies, together with our previous findings, suggest that in glioma NFIA operates at the interface of cell proliferation, fate determination, and tumorigenesis. Therefore, to examine NFIA function in a model that couples these facets of developmental and tumor biology, we used NSCs from E13.5 wild-type, NFIAϩ/Ϫ, and NFIAϪ/Ϫ embryonic cortex (das Neves et al., 1999) . Consistent with a role for NFIA in proliferation, we found that neurosphere formation and BrdU incorporation were impaired in the absence of NFIA (Fig.  6 A, E, H, I ). In parallel, we examined p21 expression and found increased levels of p21 in the absence of NFIA (Fig. 6B) . Next we examined the differentiative potential of these NSC populations, where, upon exposure to differentiation conditions, we found that NFIAϪ/Ϫ NSCs demonstrated an increase in the number of neurons and concomitant decrease in the number of nestinexpressing cells, compared to wild-type and NFIAϩ/Ϫ NSC populations ( Fig. 6C-I ). Collectively, these data indicate that loss of NFIA suppresses NSC proliferation and produces a more differentiated phenotype. That loss of NFIA alters the proliferative capacity and developmental potential of NSCs raises the question of whether the tumorigenecity of these populations is similarly impacted. To determine whether NFIA is required for tumorigenesis in an NSC model, we infected NFIAϩ/Ϫ and NFIAϪ/Ϫ NSCs with retroviruses containing EGFR-vIII and SV40-LargeT; stable lines were generated via drug selection. After confirming ectopic expression of both transgenes (Fig. 6 J, K ) , each cell line was injected subcutaneously into SCID mice, and tumorigenesis was monitored. As indicated in Figure 6N , all mice injected with NFIAϩ/Ϫ NSCs formed tumors that pathologically resembled GBM (Fig. 6M ) , while the NFIAϪ/Ϫ NSCs did not form any tumors. These data indicate that NFIA expression is required for tumorigenesis in NSCs transformed by EGFR-vIII/SV40-LargeT, thus linking its role in NSC proliferation and differentiation to cellular transformation by these oncogenic mechanisms.
Discussion
In this study, we demonstrate that the miR-223/NFIA axis regulates the proliferation of glial precursors and glioma cells through regulation of p21. During CNS development, we found that miR-223 suppresses glial precursor proliferation through repression of NFIA expression. Expression of NFIA and miR-223 in human GBM is inversely correlated, and functional studies revealed that the miR-223/NFIA axis similarly regulates the proliferation and tumorigenicity of glioma cell lines (Fig. 7) . Finally, we demonstrate that NFIA promotes the proliferation of NSC populations and is required for tumorigenesis in a NSC model of glioma. Collectively, we demonstrate that the miR-223/NFIA axis is a proliferative mechanism that is conserved across development and tumorigenesis in the CNS.
Our studies, for the first time, implicate miR-223 as a key regulator of glial precursor and glioma proliferation. Previous in silico analysis correlated miR-223 expression with the proneural subtype of GBM, though expression was never validated in pri- mary samples (Genovese et al., 2012) . While our characterization of miR-223 does not make this distinction, we found heterogeneous expression across GBM samples, suggesting that its expression may indeed be restricted to a specific GBM subtype.
Additionally, previous functional analysis suggests that miR-223 does not affect tumorigenesis in a p53Ϫ/Ϫ;PTENϪ/Ϫ mouse NSC model of GBM (Genovese et al., 2012) . This is in contrast to our results in human U87 glioma cells and is likely due to an inability to induce p21 expression in the p53Ϫ/Ϫ;PTENϪ/Ϫ NSC model, thereby attenuating the effects of miR-223/NFIA regulatory axis in this context. That U87 cells contain intact p53 (Gomez-Manzano et al., 1997) , together with the p53Ϫ/Ϫ; PTENϪ/Ϫ NSC results, suggest that suppression of glioma growth by miR-223 requires intact p53. Put together, it appears that p53 functions as a permissive factor in the transcriptional interplay between NFIA and p21 ( Fig. 7) , where modulation of NFIA expression influences the repression of p21, but not its activation. Therefore, in cases where NFIA expression is reduced, the concordant upregulation of p21, and subsequent suppression of proliferation, would require the presence of p53, a wellestablished inducer of p21 expression. Indeed, repression of glial precursor proliferation by miR-223 during development occurs in the presence of p53, further supporting this notion. Previous studies have implicated miR-223 in tumorigenesis, though its role varies: in gastric cancers, its expression is correlated with poor prognosis, whereas in acute myeloid leukemia (AML) it suppresses cell proliferation (Fazi et al., 2007; Sun et al., 2010) . The basis for these differences remains undefined; however, in AML, miR-223 suppresses cell growth through repression of E2Fs (Pulikkan et al., 2010) . We found that miR-223 similarly suppresses glioma cell growth, though it appears to operate through repression of NFIA and subsequent upregulation of p21 (Fig. 7) . It will be important to determine whether these represent tissue-specific mechanisms of growth suppression by miR-223 or are conserved across tissues and tumor types. That NFIA is also expressed in the myeloid lineage suggests that it is possible that the miR-223/NFIA/p21 axis is conserved in AML (Fazi et al., 2005) . Alternatively, one explanation for the potentially disparate mechanisms of miR-223 action across tumors is that the impact of a given microRNA on cell physiology is largely dependent upon the repertoire of available targets. Therefore, it is possible that in the presence of NFIA (and p53), miR-223 suppresses cell proliferation, and in the absence of NFIA (or p53) it does not. Further analysis correlating miR-223 function and the expression of its targets across tumor types, and normal counterparts, will reveal new insights into the diversity of cellular processes it impacts.
While the expression patterns of miR-223 and NFIA in GBM are negatively correlated (Fig. 3) , there are tumors that contain high miR-223 and NFIA expression and likely contain overlapping patterns of expression. One explanation for such a phenomenon is that other regulatory mechanisms may override miR-223 inhibition of NFIA in this context. For example, NFIA is regulated by Sox9 and Notch signaling (Kang et al., 2012; Namihira et al., 2009) ; therefore, if Sox9 expression or Notch activation is elevated, the amount of NFIA transcript is also likely to be elevated, which could titrate away the effects of the miR-223 inhibition of NFIA. The converse is also true; other miR-223 targets may be elevated in a subset of GBMs, serving as an miR-223 "sink," allowing for its effect on NFIA expression to minimized. Given the heterogeneous and genetically aberrant nature of GBM, these scenarios are likely and further illustrate the importance in defining the molecular and cellular signatures of these tumors.
The basis for our glioma studies is that miR-223 represses NFIA expression in the developing CNS and that this relationship regulates glial precursor proliferation. The relationship between miR-223 and NFIA was initially described during hematopoiesis, where repression of NFIA by miR-223 promoted granulocyte differentiation (Fazi et al., 2005) . While the effects of miR-223 in the developing CNS appear to be restricted to glial precursor proliferation, we previously found that inhibition of NFIA blocks gliogenesis and promotes neuronal differentiation (Deneen et al.,
2006). Analysis of NFIAϪ/Ϫ NSCs corroborates these findings and, together with its role in granulocyte development, suggests that NFIA functions as a suppressor of differentiation in these lineages. The suppression of differentiation is generally balanced by a concomitant promotion of cellular proliferation, suggesting that NFIA itself promotes cell proliferation. This is supported by our observations that it rescues cell proliferation defects in the presence of miR-223 in both chick spinal cord and in U87 glioma cell lines. Moreover, we found that neurosphere production and BrdU incorporation are significantly decreased in NFIAϪ/Ϫ NSCs, and that NFIA directly represses expression of p21, indicating that it is required for NSC proliferation as well. These findings are in contrast to previous studies in the developing hippocampus that imply NFIA suppresses precursor proliferation at late embryonic stages. While these studies did not assess NSC properties from these regions in vitro, it is likely that such differences reflect region or stage-specific functions for NFIA (Piper et al., 2010) . That NFIA itself inhibits NSC proliferation led us to further investigate its role in glioma, where we found, for the first time, that it is required for tumorigenesis. These results, combined with our Model of miR-223/NFIA axis function in tumorigenesis. miR-223 repression of NFIA expression results in derepression of p21, which influences the proliferation of precursor populations andgliomacellsintheCNS.p53isincludedasapermissivefactor,requiredforp21inductionandakey mediator of the NFIA/p21 transcriptional interplay. That deletion NFIA resulted in a complete loss of tumorigenesis in NSC populations transformed by SV40/EGFR-vIII strongly suggests that it influences otherpathwaysthatcontributetotumorigenesis.Thispossibilityisnotedbyadashedarrow.Likewise, it is possible that miR-223 also influences the expression of other targets that impact tumorigenesis, both negatively and positively, which may explain why the effects of deletion of NFIA are more profound than miR-223 overexpression.
findings that it is expressed in GBM and various grades of astrocytoma, suggest that NFIA directly contributes to the pathology of human glioma (Song et al., 2010) . Our mechanistic studies point to its repression of p21 as being a catalyst for its role in cell proliferation; however, given that none of the NFIAϪ/Ϫ;SV40;EGFR-vIII NSC populations formed tumors, it seems likely that NFIA also influences other aspects of cell physiology that contribute to oncogenesis (Fig.  7) . Previously, we found that NFIA collaborates with Sox9 to regulate a set of genes that control key aspects of glial precursor development that have implications in oncogenesis, including metabolism and cell migration (Kang et al., 2012) . Therefore, understanding how these developmental programs are reutilized during tumorigenesis may give more insight into how NFIA contributes to glioma formation. In addition to NFIA's relationship with Sox9, another set of relevant developmental relationships includes its interactions with other glial fate determinants implicated in glioma, including Olig2 and STAT3 (Ligon et al., 2007; de la Iglesia et al., 2008; Swartling et al., 2012) . NFIA associates with Olig2, and both function to repress p21, suggesting that they have either a redundant or collaborative relationship in this context . While there is no direct evidence that STAT3 and NFIA associate, they collaborate to regulate GFAP expression in differentiating astrocytes, suggesting that this relationship may serve to impair tumor proliferation, rather than promote it (Namihira et al., 2009) . Indeed, the role of STAT3 in glioma is dependent upon genetic context; therefore, it is possible that the role of NFIA in glioma is similarly nuanced and linked to its relationships with other glial fate determinants. Understanding how these key relationships that regulate glial development are reutilized and contribute to glioma formation will be critical to our understanding of this disease and its eventual treatment.
